Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 ± KN046 in HER2+ Colorectal and Biliary Tract Cancer
NCT05985707Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of anbenitamab and erfonrilimab in colorectal cancer (CRC) and biliary tract cancer (BTC) (3 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Overall Response Rate up to 24 months. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
anbenitamaberfonrilimab
03
Conditions
colorectal cancer (CRC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05985707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05985707.